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To be a service, a new surgical procedure must be 
within the capability of more than the occasional sur-
geon. In addition, the indications for its use should be 
clear, and the results should be good enough to justify 
the effort and expense. In this communication, we will 
indicate that orthotopic liver transplantation has met all 
three of these criteria. 
MATERIALS AND METHODS 
Two hundred and ninety-six patients were treated 
from March, 1963 through April, 1983. Until the end of 
1979, "conventional" immunosuppression was used with 
azathioprine and prednisone to which antilymphocytic 
globulin was usually added (1, 2). In 16 patients treated 
in 1971 and 1972, cyclophosphamide was substituted for 
azathioprine. From early 1980 onward, immunosuppres-
sion was with cyclosporine and steroids. The surgical 
and medical techniques have been described elsewhere 
(1,2). 
The results were analyzed before and after the intro-
duction of cyclosporine-steroid therapy. In the post-1980 
era, we studied a greatly expanded volume of cases, the 
use of veno-venous bypasses with and without heparin, 
and the systematic training of younger surgeons whose 
objective could be to set up new centers. In all of the 
case material, the influence of original disease upon the 
results also was examined. 
RESULTS 
SURVIVAL WITH CONVENTIONAL 
IMMUNOSUPPRESSION (1963-1979) 
From 1963 to the end of 1979, 170 consecutive patients 
were treated; which is an average case load of less than 
12 per year. Fifty-six (32.9%) recipients lived for at least 
1 year, and 32 (18.8%) are still alive with follow-up of 
31f2 to 13112 years. Six of the residual group are more than 
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10 years postoperative, and 26 are more than 5 years. 
Only one patient who lived for as long as 5 years subse-
quently died. 
The patient survival during the first 18 months is 
summarized in Table 1. The predominant mortality was 
in the first three postoperative months and was due 
mainly to technical surgical accidents, acceptance of 
recipients with hopelessly advanced disease, use of dam-
aged liver grafts, inability to control rejection, and 
a variety of infections (1, 2). Most deaths in the first 
half of the second year (Table 1) were due to chronic 
rejection (2). 
SURVIVAL WITH CYCLOSPORINE-STEROID THERAPY 
(1980-1981) 
Fourteen patients were treated in 1980 and 26 in 1982; 
follow-ups of 18 to 38 months are available for those still 
living. The I-year survival was 28/40 (70%) (Table 1). 
Three I-year survivors died in the 13th, 16th, and 20th 
months of recurrent cholangiocarcinoma, recurrent 
Budd-Chiari syndrome and chronic rejection (with an 
unsuccessful attempt at retransplantation), respectively. 
The actual 18-month survival (Table 1) was 65%, and 
the actuarial 2-year survival is projected at 60%. 
THE BREAKOUT YEAR OF 1982 
Until 1982, virtually all liver transplantations in our 
series over a span of almost 19 years were performed by 
a single surgeon (Table 2). The same surgeon also had 
performed all of the donor operations in the earliest 
years of these efforts and in all cases since 1979. The 
image created was of a procedure that was too difficult 
to be taught easily to other teams. Thus, policy changes 
were instituted upon which, it was thought, the practi-
cality of liver transplantation would hinge. 
The Donor Operations. Beginning on January 1, 1982, 
organ harvest teams which had been trained throughout 
the preceding year, assumed responsibility for 100% of 
the procurement procedures (Table 2). Any 1 of 5 faculty 
members (2 were urologists and 3 were general surgeons) 
headed the teams. In addition, training of other teams 
was begun in distant cities with the eventual objective of 
promoting graft hepatectomies by local surgeons instead 
of by mobile Pittsburgh teams. 
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TABLE 1. ACTVAL 18-MoNTH SURVIVAL OF 210 CONSECUTIVE RECIPIENTS 
Treatment No. 
Triple drug conwntional 170 120 
(1963-1979) (.58%) 
Cyclosporine-steroids 40 32 
(1980-1981) (80%) 
TABLE 2. THE SHARING OF PRIMARY OPERATIVE RESPONSIBILITY BY 
MULTIPLE SCRGEONS 
1963-1979 1980-1981 1982 1983 (4 months) 
New patients 170 40 62 24 
Total transplantations 191 45 80 34 
Transplantations by sin- 187 45 48 10 
gle surgeon (TES) 
(97.9%) 000%) (60%) (29.4%) 
Donor operations by sin- Minority" 100% 0% 0°-70 
gle surgeon (TES) 
"The majority of these donor operations at the University of Colo-
rado were by Dr. Charles Halgrimson. 
Recipient Operations. The diffusion of recipient oper-
ative responsibility from one to several surgeons also 
began in 1982 during which 40% of the patients were 
treated by young faculty members or fellows (Table 2). 
High Case Volume. The foregoing changes led to a 
considerable expansion of clinical efforts. In addition to 
the 62 primary transplantations, 18 retransplantations 
were performed, bringing the total number of liver re-
placements in 1982 to 80 (Table 2). 
A Trial of Veno- Venous Bypasses. Bypasses were used 
2 decades ago in the original trials of liver transplanta-
tion for decompression of the portal vein and inferior 
vena cava which must be obstructed during the hepatec-
tomy and actual transplantation (1). The practice was 
abandoned for many years but tried again in 12 cases 
during the summer of 1982 using pump-driven bypasses 
under systemic heparinization. Cannulas were placed 
into the vena cava (via the femoral vein) and into the 
portal vein. The physiologic condition of the recipients 
during the anhepatic phase and the ease of vascular 
suturing of the grafts were enormously improved, but it 
was difficult or impossible to reverse the heparin effect 
which was responsible for three deaths in the operating 
room. Of 12 recipients who had 14 such bypasses (two 
were at retransplantation), only 3 became long-term 
survivors. 
Subsequently, pump driven veno-venous bypasses 
without heparin were perfected in the laboratory and in 
1983 bypasses have been used for most of the adult 
patients. This technique has been satisfactory in 14 
recent transplantations and should place the operation 
of liver replacement within the grasp of a much greater 
number of surgeons. 
The Results in 1982. Half of the recipients treated 
during this time of major change are alive with follow-
ups of 5 to 16 months. The survival of the 1982 pediatric 
recipients «18 years) in 16/28 (57.1%) which is higher 
than the 15/34 (44.1%) achieved during 1982 in adults. 
Time in months 
2 6 
95 65 
(.55.9%) (33.2%) 
31 29 
(77.5%) (72.5%) 
THE PACE IN 1983 
12 
56 
(32.9%) 
28 
(70<;0) 
18 
47 
(27.6%) 
26 
(65%) 
During the first 4 months, 24 primary and 10 retrans-
plantation procedures were performed at a rate, what if 
sustained, will total 100 for the year. The new conditions 
developed in 1982 have continued with more than 70% 
of transplantations performed by young faculty members 
and fellows (Table 2) and with almost all adults having 
veno-venous bypasses. The present survival of new pa-
tients is 17/24 (70.8%), including 8/10 children and 
9/14 adults. 
THE INFLUENCE OF DISEASE UPON RESULTS 
None of the diseases for which transplantation has 
been performed can be categorically excluded from future 
trials in spite of a high incidence of recurrence of the 
original disease which has been documented with pri-
mary hepatic malignancies (1, 2) and with chronic active 
hepatitis in B virus carriers (2). Recurrence of Budd-
Chiari syndrome (2, 3) and primary biliary cirrhosis (3) 
have been less commonly seen. 
The I-year and current patient survival before and 
after the introduction of cyclosporine-steroid therapy is 
summarized in Table 3 for each main disease category; 
237 consecutive patients were included whose transplan-
tations were at least 1 year ago with the assumption that 
this follow-up period would permit detection of aggres-
sively evolving recurrences. The only obvious conclusion 
is that the results have improved after the introduction 
of cyclosporine-steroid therapy no matter what the orig-
inal diagnosis. It is noteworthy that no patients with 
alcoholic cirrhosis have been included in the cyclosporine 
series, a selection bias that will not be acceptable in the 
future. Alcoholic recipients from our earlier experience 
have been followed for as long as a decade. 
THE INFLUENCE OF DISEASE STAGE UPON RESULTS 
The stage of the original disease was of greater prog-
nostic importance than its nature. The stage factor was 
examined in 114 consecutive patients treated in the 
cyclosporine-steroid era from 3 to 38 months ago. Pa-
tients who were not continuously hospitalized prior to 
operation were called Class I. Those who were hospital-
ized most of the time but not in Intensive Care Units 
were classed as Class II. Recipients who were taken from 
an Intensive Care Unit to the operating room were 
termed Class III. These last patients usually were men-
tally obtunded or unconscious. Many had the hepatore-
nal syndrome and most were ventilator-dependent. The 
majority had active gastrointestinal bleeding. 
The perioperative mortality was almost 60% in the 
Class III patients (Table 4). In contrast, the mortality in 
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TABLE 3. INFLUENCE OF DISEASE UPON I YEAR AND SUBSEQCENT Sl'R\'IVAL IN :237 PATIENTS' 
Conventional therapy Cye los pori ne" st e roids 
-" "----" ------_ .. _- ----------
!'Jo. 1 year "'ow· :'\0. 1 )'ear ;\'ow" 
Biliary atresia 51 14 EOTp~F 7 (14)0) 11 6 ri4KR~<F 6 (.'i4 .. Di~iF 
Nonalcoholic cirrhosis 46 16 (34.8%) 10 (21.7%) 16 9 (56.3%) 8 (50S,) 
Primary liver malignancy 18 5 (27.8%) 1 (5.6%) 9 6 (66.7%) 4 (44.4 cC) 
a-I-antitrypsin deficiency 11 6 (54.5SO) 5 (45.5%) 6 3 (SO':';;) :1 (SO"C) 
Other inborn errors d 4 2 (SO)e.) 1 (25%) 4 4(100<;,) 4 (100<:e) 
Alcoholic cirrhosis 15 4 (26.7%) 3 (2M;') 0 
Primary biliary cirrhosis 6 1 (16.7%) 1 (16.7%) 6 5 (83.3%) 5 (83.:3SC) 
Sclerosing cholangitis 7 2 (28.6%) 0(0%) 3 2 (66.7%) 1 (:33.3S') 
Secondary biliary cirrhosis 4 3 (75%) 2 (50%) 5 1 (20%) 1 EOM~EF 
Budd-Chiari syndrome 1 1 (100%) 1 (100%) 3 3 (100%) 1 (33.3SC) 
Miscellaneous' 7 2 (28.6%) 1 (14.3%) 4 3 (75%) 3 (75S;) 
, The same case material was analyzed in detail elsewhere (2) but with shorter follow-ups. 
b Follow-ups 3th to 131/2 years. 
, Follow-ups 1 to 31/. years. 
d Wilson's disease (3 examples), tyrosinemia (2 examples), glycogen storage disease (2 examples), and sea blue histiocyte syndrome (1 sample). 
• Neonatal hepatitis (3 examples), congenital hepatic fibrosis (2 examples), Byler's disease (2 examples), adenomatosis. hem achromatosis, 
protoporphyria, and acute hepatitis B (1 example each). 
TABLE 4. EFFECT OF DISEASE STAGE ON 6-WEEK SCRVIVAL (114 
CONSECUTIVE PATIENTS) 
Class 
I 
II 
III 
Definition 
Outpatient care-dependent 
Hospital care-dependent 
Intensive Care Unit-dependent 
No. Survival (SC) 
63 68 
25 84 
26 42 
the first 6 weeks was only 16% in Class II patients. The 
somewhat higher mortality (32%) in Class I patients was 
partly explained by the fact that many of these recipients 
had undergone operations in or around the hepatic hilum 
(such as portacaval shunt or biliary tract reconstruction) 
which greatly increase the technical risk (2). Such pa-
tients were accepted for candidacy only if they were in 
the kind of reasonable metabolic state that tended to 
place them in the Class I category. 
DISCUSSION 
With improved immunosuppression that became avail-
able almost 3112 years ago, came a revitalization of inter-
est in hepatic transplantation. In spite of its use in most 
cases for pathologic conditions which will someday be 
viewed as unrealistically advanced, the number of succes-
fulliver replacements has increased sharply. 
Continuing observation of the first patients treated 
with cyclosporine-steroid therapy has dispelled skepti-
cism about the ability to use cyclosporine chronically. 
Forty-two patients have now been followed for at least 1 
year after liver transplantation under cyclosporine-ste-
roid therapy. Six deaths occurred after 1 year and all but 
two were caused by recurrence of the original disease 
(two examples of metastases from primary hepatic ma-
lignancies, one each of recurrent Budd-Chiari syndrome 
and chronic B virus hepatitis). One patient died of prob-
able airway obstruction secondary to acute tonsillitis. 
Only one patient lost a graft to chronic rejection. The 
degree of rehabilitation of long-term survivors has been 
essentially complete. 
The mystique surrounding liver transplantation 
largely has been dispelled by events of the last 2 years at 
our institution and elsewhere. Other units in the United 
States and in other countries have been able to mount 
effective programs. In Pittsburgh, more than two thirds 
of the liver transplantation operations are now being 
done by young faculty members and by surgeons in 
training. The ease with which the admittedly difficult 
operation can be performed is being reduced with the 
pump-driven nonheparin bypasses that are being used 
this year for the first time. 
SUMMARY 
Liver transplantation has been developed to the point 
of a service operation, the exploitation of which depends 
upon the estblishment of multiple regional centers. The 
increased use of this procedure will permit the delivery 
of optimum health care to victims of endstage liver 
disease. 
REFERENCES 
1. Starzl TE (with the assistance of Putnam CW). Experience in 
hepatic transplantation. Philadelphia: W. B. Saunders Co., 1969. 
2. Starzl TE, Iwasatuki I, Van Thiel DH, et al. Evolution of liver 
transplantation. Hepatology 1982; 2:614-636. 
3. Caine RY, Williams R, Lindop M, et al. Improved survival after 
orthotopic liver grafting. Br ~ed J 1981; 283: 1105-118. 
